Giovannelli e Associati advised Neopharmed Gentili on the acquisition of the entire share capital of Valeas

Pubblicato da Giovannelli e Associati il 10/08/2022

Giovannelli e Associati assisted Neopharmed Gentili, a pharmaceutical company specializing in the commercialization of high-value therapeutic solutions controlled by Ardian together with the Del Bono family, in the acquisition of the entire share capital of Valeas, a Milan-based pharmaceutical company active in the pediatric, bronchopneumological, rhinopneumatic and neuropsychiatric sectors.

Fabrizio Scaparro led the firm’s team, composed by senior associate Paola Pagani and associates Lilia Montella and Filippo Noci for corporate aspects, partner Riccardo Pontremoli and associate Carlo Pilia for regulatory and golden power aspects, partner Alessandra Feller and associate Ginevra Lombardi for IP and privacy aspects, and of counsel Giuseppe Matarazzo and associate Katie Pesenti for labor aspects.

Neopharmed Gentili – Valeas – NT+ Diritto – IlSole24Ore – 29.07.2022

Giovannelli e Associati with Neva SGR on the investment round of Casavo

HOT TAX TOPIC – RELOCATION TO ITALY OF INDIVIDUALS: AN OVERVIEW ON TAX AND IMMIGRATION INCENTIVES (WITH FOCUS ON CRYPTOCURRENCIES)

Giovannelli e Associati advised Neopharmed Gentili on the acquisition of the entire share capital of Valeas

Media correlati

Giovannelli e Associati with Nebula Aurea BidCo (White Bridge Investments III) on the voluntary all-inclusive offer on shares and warrants of Reevo

Giovannelli e Associati announces a round of promotions

Giovannelli e Associati awarded for the Venture Capital practice in 2022 in the context of the Class MF regional Awards, an initiative sponsored by Class Editori